Preferred Label : brivaracetam;
MeSH note : has antiepileptic activity; structure in first source;
MeSH synonym : 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide; (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide; 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-;
MeSH hyponym : UCB34714; UCB-34714;
Is substance : O;
UNII : U863JGG2IA;
Origin ID : C482793;
UMLS CUI : C1699861;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3402018/fr/briviact-brivaracetam-epilepsie-de-l-enfant-et-de-l-adolescent-2-a-15-ans-inclus
2023
false
false
false
France
drug therapy, combination
treatment outcome
insurance, health, reimbursement
anticonvulsants
brivaracetam
evaluation of the transparency committee
child
adolescent
epilepsies, partial
brivaracetam
---
https://www.ema.europa.eu/medicines/human/EPAR/briviact-italy-nubriveo
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
brivaracetam
brivaracetam
brivaracetam
europe
drug approval
drug therapy, combination
anticonvulsants
anticonvulsants
adult
adolescent
epilepsies, partial
drug interactions
pregnancy
breast feeding
administration, oral
infusions, intravenous
drug monitoring
product surveillance, postmarketing
contraception
aged
SV2A protein, human
drug evaluation, preclinical
injections, intravenous
brivaracetam
brivaracetam
pyrrolidinones
pyrrolidinones
membrane glycoproteins
nerve tissue proteins
---
http://www.has-sante.fr/portail/jcms/c_2664617/fr/briviact
http://www.has-sante.fr/portail/jcms/c_2664617/fr/briviact-brivaracetam-antiepileptique
2016
false
false
false
France
French
treatment outcome
brivaracetam
brivaracetam
brivaracetam
drug therapy, combination
anticonvulsants
anticonvulsants
adult
adolescent
epilepsies, partial
administration, oral
infusions, intravenous
injections, intravenous
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
brivaracetam
brivaracetam
pyrrolidinones
pyrrolidinones
---